Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-06

FDA Approved: OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE — Original Application (Camber Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves Camber Pharmaceuticals' generic triple-combination tablet of olmesartan medoxomil, amlodipine, and hydrochlorothiazide for essential hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Olmesartan medoxomil amlodipine and hydrochlorothiazide (olmesartan medoxomil; amlodipine; hydrochlorothiazide)

Snippet

ORIG AP for OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE (OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE)